Study compares criteria for monitoring response to CRC treatment

04/11/2013 | MolecularImaging.net

The PET Response Criteria in Solid Tumors and criteria from the European Organization for Research and Treatment of Cancer are similarly useful for measuring the response of patients with colorectal cancer to cycles of irinotecan and cetuximab using PET/CT, according to a study published in The Journal of Nuclear Medicine. However, the researchers found that PERCIST was better suited for widespread use because the criteria were less sensitive to differences between observers, allowing for greater consistency.

View Full Article in:

MolecularImaging.net

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID